Time-specific gene knockout technology: model establishment, present and future

doi:10.3969/j.issn.2095-4344.2016.18.021

Abstract

Abstract:

BACKGROUND: The target gene cannot be deleted at specific time by using conditional gene knockout system. Most gene knockout animals cannot survive during embryonic development and after birth, which limits the study of gene function.

OBJECTIVE: To review the recent advances about time-specific gene knockout technology.

METHODS: An online search in PubMed was performed from the initial stage of database establishment to August 2014. The key words were gene knockout, inducer and Cre/loxP system. The repeated experiment and unrelated articles were excluded during primary search. A summary was made by analyzing time-specific gene knockout technology.

RESULTS AND CONCLUTION: Most important gene knockout animals could not survive after birth, or die at early embryonic stage due to serious physical defects induced by an important gene deletion. Therefore, the progress in the functionality of a gene at a particular time, the genetic characteristics of an individual organism in a particular developmental period, and the treatment of certain acquired disease at a given time have been limited because of the limitations of research methods. However, the occurrence of conditional gene knockout animals, especially time-specific knockout animals, provides a research model for the study of these areas. This study reviewed the recent advances, development and application about time-specific gene knockout animals, and discussed the significance and broad prospects of time-specific gene knockout technology of specific genes in the field of scientific research.
中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

Key words: Gene Knockout Techniques, Gene Deletion, Chimera, Cell Division

Chen Rui-jun, Huang Xiao-feng, Zhang Fang-ming. Time-specific gene knockout technology: model establishment, present and future [J]. Chinese Journal of Tissue Engineering Research, 2016, 20(18): 2725-2730.

Figures/Tables 1

References

[1] Capecchi MR. Altering the genome by homologous recombination. Science. 1989;244(4910):1288-1292.

[2] Capecchi MR. The new mouse genetics: altering the genome by gene targeting. Trends Genet. 1989;5(3): 70-76.

[3] Babinet C, Cohen-Tannoudji M. Genome engineering via homologous recombination in mouse embryonic stem (ES) cells: an amazingly versatile tool for the study of mammalian biology. An Acad Bras Cienc. 2001 ;73(3):365-383.

[4] Mansour SL. Gene targeting in murine embryonic stem cells: introduction of specific alterations into the mammalian genome. Genet Anal Tech Appl. 1990; 7(8): 219-227.

[5] Melton DW. The use of gene targeting to develop animal models for human genetic diseases. Biochem Soc Trans. 1990;18(6):1035-1039.

[6] Zimmer A. Manipulating the genome by homologous recombination in embryonic stem cells. Annu Rev Neurosci. 1992;15:115-137.

[7] Capecchi MR. Targeted gene replacement. Sci Am. 1994;270(3):52-59.

[8] Bradley A, Ramírez-Solis R, Zheng H, et al. Genetic manipulation of the mouse via gene targeting in embryonic stem cells. Ciba Found Symp. 1992;165: 256-269; discussion 269-276.

[9] Smith GR. How homologous recombination is initiated: unexpected evidence for single-strand nicks from v(d)j site-specific recombination. Cell. 2004;117(2):146-148.

[10] Morrow B, Kucherlapati R. Gene targeting in mammalian cells by homologous recombination. Curr Opin Biotechnol. 1993;4(5):577-582.

[11] Waldman AS. Targeted homologous recombination in mammalian cells. Crit Rev Oncol Hematol. 1992;12(1): 49-64.

[12] Sollars PJ, Weiser MJ, Kudwa AE, et al. Altered entrainment to the day/night cycle attenuates the daily rise in circulating corticosterone in the mouse. PLoS One. 2014;9(11):e111944.

[13] Girardet C, Becquet D, Blanchard MP, et al. Neuroglial and synaptic rearrangements associated with photic entrainment of the circadian clock in the suprachiasmatic nucleus. Eur J Neurosci. 2010; 32(12): 2133-2142.

[14] Harmar AJ. An essential role for peptidergic signalling in the control of circadian rhythms in the suprachiasmatic nuclei. J Neuroendocrinol. 2003; 15(4): 335-338.

[15] Parkitna JR, Engblom D, Schütz G. Generation of Cre recombinase-expressing transgenic mice using bacterial artificial chromosomes. Methods Mol Biol. 2009;530:325-342.

[16] Nagy A, Mar L, Watts G. Creation and use of a cre recombinase transgenic database. Methods Mol Biol. 2009;530:365-378.

[17] Wouterlood FG, Bloem B, Mansvelder HD, et al. A fourth generation of neuroanatomical tracing techniques: exploiting the offspring of genetic engineering. J Neurosci Methods. 2014;235:331-348.

[18] Król JE, Wojtowicz AJ, Rogers LM, et al. Invasion of E. coli biofilms by antibiotic resistance plasmids. Plasmid. 2013;70(1):110-119.

[19] Peng H, Wu Y, Zhang Y. Efficient delivery of DNA and morpholinos into mouse preimplantation embryos by electroporation. PLoS One. 2012;7(8):e43748.

[20] Guo L, Ge J, Wang S, et al. A novel method for efficient delivery of stem cells to the ischemic brain. Stem Cell Res Ther. 2013;4(5):116.

[21] Krivokharchenko A, Karmenyan A, Sarkisov O, et al. Laser fusion of mouse embryonic cells and intra-embryonic fusion of blastomeres without affecting the embryo integrity. PLoS One. 2012;7(12):e50029.

[22] Thomas KR, Capecchi MR. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell. 1987;51(3):503-512.

[23] Tsien JZ, Chen DF, Gerber D, et al. Subregion- and cell type-restricted gene knockout in mouse brain. Cell. 1996; 87(7):1317-1326.

[24] Sauer B. Inducible gene targeting in mice using the Cre/lox system. Methods. 1998;14(4):381-392.

[25] Sauer B. Cre/lox: one more step in the taming of the genome. Endocrine. 2002;19(3):221-228.

[26] Gavériaux-Ruff C, Kieffer BL. Conditional gene targeting in the mouse nervous system: Insights into brain function and diseases. Pharmacol Ther. 2007;113(3):619-634.

[27] Branda CS, Dymecki SM. Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. Dev Cell. 2004;6(1):7-28.

[28] Misra RP, Duncan SA. Gene targeting in the mouse: advances in introduction of transgenes into the genome by homologous recombination. Endocrine. 2002;19(3):229-238.

[29] Ray MK, Fagan SP, Brunicardi FC. The Cre-loxP system: a versatile tool for targeting genes in a cell- and stage-specific manner. Cell Transplant. 2000; 9(6):805-815.

[30] Yoshimura I, Suzuki S, Hayakawa M. Application of Cre-loxP system to the urinary tract and cancer gene therapy. Mol Urol. 2001;5(2):81-84.

[31] Rosenberg MP. Gene knockout and transgenic technologies in risk assessment: the next generation. Mol Carcinog. 1997;20(3):262-274.

[32] Gu H, Marth JD, Orban PC, et al. Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting. Science. 1994;265 (5168):103-106.

[33] Sparks MA, Makhanova NA, Griffiths RC, et al. Thromboxane receptors in smooth muscle promote hypertension, vascular remodeling, and sudden death. Hypertension. 2013;61(1): 166-173.

[34] Polykratis A, van Loo G, Xanthoulea S, et al. Conditional targeting of tumor necrosis factor receptor-associated factor 6 reveals opposing functions of Toll-like receptor signaling in endothelial and myeloid cells in a mouse model of atherosclerosis. Circulation. 2012;126(14):1739-1751.

[35] Wei Y, Nazari-Jahantigh M, Neth P, et al. MicroRNA-126, -145, and -155: a therapeutic triad in atherosclerosis? Arterioscler Thromb Vasc Biol. 2013; 33(3):449-454.

[36] Lin CI, Barletta JA, Nehs MA, et al. Thyroid-specific knockout of the tumor suppressor mitogen-inducible gene 6 activates epidermal growth factor receptor signaling pathways and suppresses nuclear factor-κB activity. Surgery. 2011;150(6):1295-1302.

[37] Morioka Y, Isotani A, Oshima RG, et al. Placenta- specific gene activation and inactivation using integrase-defective lentiviral vectors with the Cre/LoxP system. Genesis. 2009;47(12):793-798.

[38] Banasik MB, McCray PB Jr. Integrase-defective lentiviral vectors: progress and applications. Gene Ther. 2010;17(2):150-157.

[39] Staunstrup NH, Mikkelsen JG. Integrase-defective lentiviral vectors--a stage for nonviral integration machineries. Curr Gene Ther. 2011;11(5):350-362.

[40] Negri DR, Michelini Z, Bona R, et al. Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity. Expert Opin Biol Ther. 2011;11(6):739-750.

[41] Liu KC, Lin BS, Gao AD, et al. Integrase-deficient lentivirus: opportunities and challenges for human gene therapy. Curr Gene Ther. 2014;14(5):352-364.

[42] Ward JM, Elmore SA, Foley JF. Pathology methods for the evaluation of embryonic and perinatal developmental defects and lethality in genetically engineered mice. Vet Pathol. 2012;49(1):71-84.

[43] Chu L, Li J, Liu Y, et al. Targeted gene disruption in zebrafish reveals noncanonical functions of LH signaling in reproduction. Mol Endocrinol. 2014;28(11):1785-1795.

[44] Kumar TR. What have we learned about gonadotropin function from gonadotropin subunit and receptor knockout mice? Reproduction. 2005;130(3):293-302.

[45] Shimizu E, Tang YP, Rampon C, et al. NMDA receptor-dependent synaptic reinforcement as a crucial process for memory consolidation. Science. 2000;290(5494):1170-1174.

[46] Werfel S, Jungmann A, Lehmann L, et al. Rapid and highly efficient inducible cardiac gene knockout in adult mice using AAV-mediated expression of Cre recombinase. Cardiovasc Res. 2014;104(1):15-23.

[47] Sabharwal R, Chapleau MW. Autonomic, locomotor and cardiac abnormalities in a mouse model of muscular dystrophy: targeting the renin-angiotensin system. Exp Physiol. 2014;99(4):627-631.

[48] Heine HL, Leong HS, Rossi FM, et al. Strategies of conditional gene expression in myocardium: an overview. Methods Mol Med. 2005;112:109-154.

[49] Choi CI, Yoon SP, Choi JM, et al. Simultaneous deletion of floxed genes mediated by CaMKIIα-Cre in the brain and in male germ cells: application to conditional and conventional disruption of Goα. Exp Mol Med. 2014;46:e93.

[50] Mo L, Cheng J, Lee EY, et al. Gene deletion in urothelium by specific expression of Cre recombinase. Am J Physiol Renal Physiol. 2005;289(3):F562-568.

[51] Casanova E, Fehsenfeld S, Mantamadiotis T, et al. A CamKIIalpha iCre BAC allows brain-specific gene inactivation. Genesis. 2001;31(1):37-42.

[52] Bex A, Vooijs M, Horenblas S, et al. Controlling gene expression in the urothelium using transgenic mice with inducible bladder specific Cre-lox recombination. J Urol. 2002;168(6):2641-2644.

[53] Castrop H, Oppermann M, Weiss Y, et al. Reporter gene recombination in juxtaglomerular granular and collecting duct cells by human renin promoter-Cre recombinase transgene. Physiol Genomics. 2006; 25(2):277-285.

[54] Kistner A, Gossen M, Zimmermann F, et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A. 1996;93(20):10933-10938.

[55] Perl AK, Wert SE, Nagy A, et al. Early restriction of peripheral and proximal cell lineages during formation of the lung. Proc Natl Acad Sci U S A. 2002;99(16): 10482-10487.

[56] Xie W, Chow LT, Paterson AJ, et al. Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGFalpha expression in transgenic mice. Oncogene. 1999;18(24):3593-3607.

[57] Goldfless SJ, Belmont BJ, de Paz AM, et al. Direct and specific chemical control of eukaryotic translation with a synthetic RNA-protein interaction. Nucleic Acids Res. 2012;40(9):e64.

[58] Meitert J, Aram R, Wiesemann K, et al. Monitoring the expression level of coding and non-coding RNAs using a TetR inducing aptamer tag. Bioorg Med Chem. 2013; 21(20):6233-6238.

[59] Belmont BJ, Niles JC. Inducible control of subcellular RNA localization using a synthetic protein-RNA aptamer interaction. PLoS One. 2012;7(10):e46868.

[60] Chaiyachati BH, Kaundal RK, Zhao J, et al. LoxP-FRT Trap (LOFT): a simple and flexible system for conventional and reversible gene targeting. BMC Biol. 2012;10:96.